WASHC3

Summary

WASHC3 (WASH complex subunit 3, HGNC:24256) is a protein-coding gene on chromosome 12q23.2, encoding WASH complex subunit 3 (Q9Y3C0). Acts as a component of the WASH core complex that functions as a nucleation-promoting factor (NPF) at the surface of endosomes, where it recruits and activates the Arp2/3 complex to induce actin polymerization, playing a key role in the fission of tubules that serve as transport…. It is a selective cancer dependency (DepMap: 17.1% of cell lines).

Predicted to be involved in actin filament polymerization and exocytosis. Part of WASH complex.

Source: NCBI Gene 51019 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 5
• Clinical variants (ClinVar): 29 total
• Cancer dependency (DepMap): dependent in 17.1% of screened cell lines
• MANE Select transcript: NM_016053

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24256
Approved symbol	WASHC3
Name	WASH complex subunit 3
Location	12q23.2
Locus type	gene with protein product
Status	Approved
Aliases	CGI-116
Ensembl gene	ENSG00000120860
Ensembl biotype	protein_coding
OMIM	619925
Entrez	51019

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 7 protein_coding, 5 nonsense_mediated_decay, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000240079, ENST00000326351, ENST00000500685, ENST00000535501, ENST00000536197, ENST00000536930, ENST00000538761, ENST00000539515, ENST00000540536, ENST00000541569, ENST00000542923, ENST00000544341, ENST00000545679, ENST00000869761, ENST00000869762, ENST00000869763, ENST00000933111

RefSeq mRNA: 2 — MANE Select: NM_016053 NM_001301107, NM_016053

CCDS: CCDS44959, CCDS73512

Canonical transcript exons

ENST00000240079 — 7 exons

Exon	Start	End
ENSE00001373355	102061912	102061991
ENSE00002320257	102012840	102013192
ENSE00003521224	102025974	102026038
ENSE00003528244	102046054	102046119
ENSE00003571942	102044105	102044212
ENSE00003594910	102039868	102039978
ENSE00003689262	102061248	102061346

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 98.63.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.2685 / max 487.5155, expressed in 1806 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
132924	23.1612	1805
132925	0.8272	560
132926	0.1994	42
132927	0.0585	9
132928	0.0223	3

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	98.63	gold quality
right testis	UBERON:0004534	98.62	gold quality
testis	UBERON:0000473	97.44	gold quality
calcaneal tendon	UBERON:0003701	97.26	gold quality
decidua	UBERON:0002450	96.71	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.28	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.65	gold quality
lower esophagus	UBERON:0013473	95.64	gold quality
tendon	UBERON:0000043	95.60	gold quality
spinal cord	UBERON:0002240	95.59	gold quality
sperm	CL:0000019	95.56	gold quality
adult organism	UBERON:0007023	95.24	gold quality
popliteal artery	UBERON:0002250	95.23	gold quality
tibial artery	UBERON:0007610	95.23	gold quality
left coronary artery	UBERON:0001626	95.13	gold quality
male germ cell	CL:0000015	94.99	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.98	gold quality
aorta	UBERON:0000947	94.94	gold quality
descending thoracic aorta	UBERON:0002345	94.83	gold quality
right coronary artery	UBERON:0001625	94.79	gold quality
adenohypophysis	UBERON:0002196	94.70	gold quality
thoracic aorta	UBERON:0001515	94.68	gold quality
ascending aorta	UBERON:0001496	94.64	gold quality
caudate nucleus	UBERON:0001873	94.59	gold quality
corpus callosum	UBERON:0002336	94.59	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.59	gold quality
nucleus accumbens	UBERON:0001882	94.53	gold quality
coronary artery	UBERON:0001621	94.49	gold quality
rectum	UBERON:0001052	94.40	gold quality
amygdala	UBERON:0001876	94.39	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	27.88
E-MTAB-6058	no	203.67
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

21 targeting WASHC3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-100-3P	99.20	67.33	672
HSA-MIR-5008-5P	98.42	65.87	1019
HSA-MIR-484	98.16	66.92	1074
HSA-MIR-3155A	98.16	66.09	965
HSA-MIR-3155B	98.16	66.09	965
HSA-MIR-4736	97.96	65.89	1287
HSA-MIR-600	97.07	66.73	1259
HSA-MIR-7108-5P	96.42	66.17	598
HSA-MIR-6851-3P	95.73	65.11	688

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 17.1% of screened cell lines.

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	washc3	ENSDARG00000045563
mus_musculus	Washc3	ENSMUSG00000020056
rattus_norvegicus	Washc3	ENSRNOG00000005102
drosophila_melanogaster	CCDC53	FBGN0031979
caenorhabditis_elegans		WBGENE00019125

Protein

Protein identifiers

WASH complex subunit 3 — Q9Y3C0 (reviewed: Q9Y3C0)

Alternative names: Coiled-coil domain-containing protein 53

All UniProt accessions (8): F5GWI9, F5GXZ4, F5GXZ7, F5GZ97, F5H0A7, F5H2P1, Q9Y3C0, H0YGN0

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a component of the WASH core complex that functions as a nucleation-promoting factor (NPF) at the surface of endosomes, where it recruits and activates the Arp2/3 complex to induce actin polymerization, playing a key role in the fission of tubules that serve as transport intermediates during endosome sorting.

Subunit / interactions. Component of the WASH core complex also described as WASH regulatory complex (SHRC) composed of WASH (WASHC1, WASH2P or WASH3P), WASHC2 (WASHC2A or WASHC2C), WASHC3, WASHC4 and WASHC5. The WASH core complex associates via WASHC2 with the F-actin-capping protein dimer (formed by CAPZA1, CAPZA2 or CAPZA3 and CAPZB) in a transient or substoichiometric manner which was initially described as WASH complex.

Subcellular location. Early endosome.

Similarity. Belongs to the CCDC53 family.

RefSeq proteins (2): NP_001288036, NP_057137* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019309	WASHC3	Family

Pfam: PF10152

UniProt features (8 total): region of interest 2, sequence conflict 2, chain 1, coiled-coil region 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y3C0-F1	70.96	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 149 (showing top): GOBP_REGULATION_OF_ACTIN_NUCLEATION, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS, TERAMOTO_OPN_TARGETS_CLUSTER_5, CAIRO_HEPATOBLASTOMA_CLASSES_DN, GOBP_EXOCYTOSIS, GOBP_ACTIN_FILAMENT_ORGANIZATION, GOBP_SECRETION, GOBP_REGULATION_OF_ARP2_3_COMPLEX_MEDIATED_ACTIN_NUCLEATION, LIU_CMYB_TARGETS_UP, GOBP_ARP2_3_COMPLEX_MEDIATED_ACTIN_NUCLEATION, GOBP_ACTIN_NUCLEATION, LIU_VMYB_TARGETS_UP, GOBP_REGULATION_OF_CYTOSKELETON_ORGANIZATION, CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP

GO Biological Process (5): exocytosis (GO:0006887), protein transport (GO:0015031), endosomal transport (GO:0016197), actin filament polymerization (GO:0030041), regulation of Arp2/3 complex-mediated actin nucleation (GO:0034315)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): early endosome membrane (GO:0031901), WASH complex (GO:0071203), cytoplasm (GO:0005737), endosome (GO:0005768), early endosome (GO:0005769)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
vesicle-mediated transport	2
secretion by cell	1
vesicle fusion to plasma membrane	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
intracellular transport	1
actin polymerization or depolymerization	1
protein polymerization	1
Arp2/3 complex-mediated actin nucleation	1
regulation of actin nucleation	1
binding	1
early endosome	1
endosome membrane	1
cytoplasm	1
protein-containing complex	1
intracellular anatomical structure	1
cellular anatomical structure	1
endomembrane system	1
cytoplasmic vesicle	1
endosome	1

Protein interactions and networks

STRING

794 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WASHC3	WASHC5	Q12768	998
WASHC3	WASHC4	Q2M389	998
WASHC3	WASHC1	A8K0Z3	997
WASHC3	WASHC2C	Q9Y4E1	954
WASHC3	WAS	P42768	758
WASHC3	WASHC2A	Q641Q2	691
WASHC3	VPS35	Q96QK1	681
WASHC3	CCDC22	O60826	649
WASHC3	VPS29	Q9UBQ0	644
WASHC3	SNX27	Q96L92	632
WASHC3	VPS26A	O75436	621
WASHC3	CCDC93	Q567U6	621
WASHC3	SNX1	Q13596	599
WASHC3	BRK1	Q8WUW1	583
WASHC3	SNX2	P82862	544

IntAct

300 interactions, top by confidence:

A	B	Type	Score
OPTN	WASHC3	psi-mi:“MI:0915”(physical association)	0.950
WASHC3	OPTN	psi-mi:“MI:0915”(physical association)	0.950
WASHC3	HSBP1	psi-mi:“MI:0915”(physical association)	0.940
HSBP1	WASHC3	psi-mi:“MI:0915”(physical association)	0.940
WASHC3	MCRS1	psi-mi:“MI:0915”(physical association)	0.880
MCRS1	WASHC3	psi-mi:“MI:0915”(physical association)	0.880
WASHC3	NDC80	psi-mi:“MI:0915”(physical association)	0.870
NUP62	WASHC3	psi-mi:“MI:0915”(physical association)	0.870
WASHC3	NUP62	psi-mi:“MI:0915”(physical association)	0.870
NDC80	WASHC3	psi-mi:“MI:0915”(physical association)	0.870

BioGRID (240): CCDC53 (Two-hybrid), CCDC53 (Two-hybrid), CCDC53 (Two-hybrid), CCDC53 (Two-hybrid), CCDC53 (Two-hybrid), CCDC53 (Two-hybrid), CCDC53 (Two-hybrid), CCDC53 (Two-hybrid), CCDC53 (Two-hybrid), CCHCR1 (Two-hybrid), CEP55 (Two-hybrid), DTNBP1 (Two-hybrid), IFT20 (Two-hybrid), MOB1B (Two-hybrid), SYCE1 (Two-hybrid)

ESM2 similar proteins: A0AUQ6, A2BE76, O14645, O18973, O35427, O35473, O55003, O88447, O88597, P50503, Q05B58, Q12983, Q13901, Q14457, Q14AM7, Q14CZ0, Q28HY5, Q32KN2, Q32PE4, Q4A1L3, Q4A1L4, Q4A1L5, Q4R3K5, Q4R8N2, Q4RLT3, Q52LA3, Q5JSJ4, Q5NVP8, Q5R878, Q5RBU4, Q5TKA1, Q5ZHS3, Q5ZJQ3, Q68FJ8, Q6DKA1, Q6GMH0, Q6GP52, Q6PAX8, Q6X4M3, Q7TSU0

Diamond homologs: B5X3I1, Q05B58, Q55FU3, Q5RGJ6, Q6DKA1, Q9CR27, Q9VLT8, Q9Y3C0, O01901

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
WASHC3	“form complex”	“WASH complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 61 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Golgi Associated Vesicle Biogenesis	5	25.0×	4e-04

GO biological processes:

GO term	Partners	Fold	FDR
cilium assembly	6	8.3×	4e-03
protein transport	7	5.8×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

29 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	20
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1274 predictions. Top by Δscore:

Variant	Effect	Δscore
12:102025972:A:AC	donor_gain	1.0000
12:102025973:C:CT	donor_gain	1.0000
12:102025973:CT:C	donor_gain	1.0000
12:102026035:CACC:C	acceptor_gain	1.0000
12:102026037:CC:C	acceptor_gain	1.0000
12:102026038:CC:C	acceptor_gain	1.0000
12:102026039:C:CA	acceptor_loss	1.0000
12:102039976:CTG:C	acceptor_gain	1.0000
12:102044100:CTTA:C	donor_gain	1.0000
12:102044101:TTAC:T	donor_loss	1.0000
12:102044101:TTACC:T	donor_gain	1.0000
12:102044102:TAC:T	donor_loss	1.0000
12:102044102:TACCT:T	donor_gain	1.0000
12:102044103:A:AC	donor_gain	1.0000
12:102044103:AC:A	donor_gain	1.0000
12:102044103:ACCTG:A	donor_gain	1.0000
12:102044104:C:CT	donor_gain	1.0000
12:102044104:CC:C	donor_gain	1.0000
12:102044104:CCT:C	donor_gain	1.0000
12:102044104:CCTG:C	donor_gain	1.0000
12:102044104:CCTGT:C	donor_gain	1.0000
12:102044208:GACAA:G	acceptor_gain	1.0000
12:102044209:ACAA:A	acceptor_gain	1.0000
12:102044210:CAA:C	acceptor_gain	1.0000
12:102044210:CAAC:C	acceptor_gain	1.0000
12:102044211:AA:A	acceptor_gain	1.0000
12:102044213:C:CC	acceptor_gain	1.0000
12:102046050:CAAC:C	donor_loss	1.0000
12:102046051:AACC:A	donor_loss	1.0000
12:102046053:C:CA	donor_loss	1.0000

AlphaMissense

1266 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:102039878:A:G	M142T	1.000
12:102046073:A:G	L66P	1.000
12:102026007:A:C	M156R	0.999
12:102026007:A:T	M156K	0.999
12:102026009:T:A	K155N	0.999
12:102026009:T:G	K155N	0.999
12:102026011:T:C	K155E	0.999
12:102026019:A:T	I152K	0.999
12:102026034:A:T	V147E	0.999
12:102039877:C:A	M142I	0.999
12:102039877:C:G	M142I	0.999
12:102039877:C:T	M142I	0.999
12:102039878:A:C	M142R	0.999
12:102039878:A:T	M142K	0.999
12:102044211:A:G	L73S	0.999
12:102046059:C:G	A71P	0.999
12:102061276:A:G	L41P	0.999
12:102026007:A:G	M156T	0.998
12:102026019:A:C	I152R	0.998
12:102026022:G:T	A151E	0.998
12:102026034:A:G	V147A	0.998
12:102026037:C:T	G146D	0.998
12:102039888:A:C	Y139D	0.998
12:102039897:A:C	Y136D	0.998
12:102044206:A:G	S75P	0.998
12:102046115:A:G	L52P	0.998
12:102061299:A:C	F33L	0.998
12:102061299:A:T	F33L	0.998
12:102061301:A:G	F33L	0.998
12:102061309:A:G	L30P	0.998

dbSNP variants (sampled 300 via entrez): RS1000012587 (12:102051213 CG>C), RS1000015909 (12:102041551 A>G), RS1000057977 (12:102048710 T>A,C), RS1000088568 (12:102048987 T>C), RS1000184166 (12:102028631 T>C), RS1000198353 (12:102020644 T>G), RS1000246267 (12:102044432 A>G), RS1000269613 (12:102014552 T>C), RS1000308032 (12:102020997 G>A), RS1000359568 (12:102055902 G>A), RS1000404136 (12:102037152 G>C), RS1000414329 (12:102062435 T>A), RS1000419864 (12:102014222 G>A), RS1000467866 (12:102059544 G>A), RS1000499486 (12:102042926 T>C)

Disease associations

OMIM: gene MIM:619925 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST010703_2	Brain morphology (MOSTest)	3.000000e-37
GCST012227_547	Hip circumference adjusted for BMI	2.000000e-08
GCST90000025_988	Appendicular lean mass	1.000000e-25
GCST90000025_989	Appendicular lean mass	2.000000e-17
GCST90020028_1677	Hip circumference adjusted for BMI	4.000000e-11

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement
EFO:0008039	BMI-adjusted hip circumference
EFO:0004980	appendicular lean mass

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression	3
Air Pollutants	decreases expression, affects cotreatment, increases abundance, increases oxidation	2
ginger extract	affects cotreatment, affects expression, increases abundance	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
bisphenol A	increases abundance, affects cotreatment, affects expression	1
beta-lapachone	decreases expression, increases expression	1
arsenite	affects binding, increases reaction	1
cobaltous chloride	decreases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	decreases expression	1
Sunitinib	decreases expression	1
Vorinostat	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Benzo(a)pyrene	increases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Mitoxantrone	affects response to substance	1
Oils, Volatile	affects cotreatment, affects expression, increases abundance	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Selenium	decreases expression	1
Thiram	decreases expression	1
Cyclosporine	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SH21	HAP1 CCDC53 (-) 1	Cancer cell line	Male
CVCL_SH22	HAP1 CCDC53 (-) 2	Cancer cell line	Male
CVCL_SH23	HAP1 CCDC53 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice